COMMUNIQUÉS West-GlobeNewswire

Notice to convene Herantis Pharma Plc's Extraordinary General Meeting of Shareholders

19/10/2017 - 15:30

Notice to convene Herantis Pharma Plc's Extraordinary General Meeting of Shareholders Herantis Pharma Plc Company release 19 October 2017, 4:30 pm NOTICE TO CONVENE HERANTIS PHARMA PLC'S EXTRAORDINARY GENERAL MEETING OF [...]

Herantis Pharma Plc is planning a directed share issue to a limited number of investors and the company's directors regarding the financing of the Lymfactin Phase 2 clinical study

19/10/2017 - 15:00

Herantis Pharma Plc is planning a directed share issue to a limited number of investors and the company's directors regarding the financing of the Lymfactin Phase 2 clinical study Herantis Pharma Plc Company release 19 [...]

Novel Preclinical Research Tools Provide Humanized Immune Response to Advance Immunotherapeutic Development, Live Webinar Hosted by Crown Bioscience

19/10/2017 - 14:00

SANTA CLARA, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company [...]

Active Biotech's partner Teva presents new data on laquinimod for the treatment of multiple sclerosis at 7th joint ECTRIMS-ACTRIMS Meeting

19/10/2017 - 14:00

Lund, October 19, 2017 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that the collaboration partner Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present new data on laquinimod, an [...]

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...

19/10/2017 - 13:12

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l' [...]

Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financ...

19/10/2017 - 13:12

Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financiers Sanofi Société [...]

uniQure Strengthens Intellectual Property Portfolio with Acquisition of Patent Family Providing Broad Protection of the Hyperactive Padua Variant of Factor IX (FIX-Padua)

19/10/2017 - 13:05

~ Issued Patent in the U.S. Covers Use of FIX-Padua in Gene Therapy ~ ~ Divisional patent applications filed to further strengthen Padua intellectual property position ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, [...]

uniQure Announces Hemophilia B Gene Therapy Program To Enter Pivotal Study With FIX-Padua Variant in 2018

19/10/2017 - 13:00

~ AMT-060 with the FIX-Padua Modification (AMT-061) Demonstrates Substantial Increase in FIX Activity in Non-human Primates ~ ~ Plans to Initiate Pivotal Study with Enhanced AMT-061 in 2018 ~ ~ Achieves Alignment with [...]

Conférence de presse du mercredi à l'occasion de la Conférence mondiale sur le cancer du poumon : Progrès PD-1/PD-L1 et interventions pour prévenir et traiter le cancer du poumon

19/10/2017 - 11:26

YOKOHAMA, Japon, 2017-10-19 (GLOBE NEWSWIRE) -- La conférence de presse finale organisée à l'occasion de la 18 e Conférence mondiale sur le cancer du poumon (WCLC) de l'Association internationale pour l'étude du cancer [...]

HOMEVI S.A.S. ISSUES A NOTICE OF CONDITIONAL REDEMPTION OF ITS €608 MILLION 6.875% SENIOR SECURED NOTES DUE 2021 AND ITS €200 MILLION FLOATING RATE SENIOR SECURED NOTES DUE 2021

19/10/2017 - 09:00

Suresnes, October 19, 2017 - 9:00 am CET HomeVi S.A.S. ("HomeVi"), today announces that it has issued a notice of conditional redemption for all of its outstanding €608,000,000 6 7 / 8 % Senior Secured Notes due 2021 ( [...]

Helsinn Announces Attendance at the CPhI 2017 Conference in Frankfurt

19/10/2017 - 09:00

Helsinn Announces Attendance at the CPhI 2017 Conference in Frankfurt Helsinn will be attending between 24-26 October at Booth Number 61B20, Hall 6.1 on the Integrated Pharma Gold corridor Helsinn will introduce its [...]

The Board of Directors of Nexstim Plc resolved on amendments of the stock options 2016 and on a new stock option plan for the CEO

19/10/2017 - 08:00

Company Announcement, Helsinki, 19 October 2017 at 9:00 AM The Board of Directors of Nexstim Plc resolved on amendments of the stock options 2016 and on a new stock option plan for the CEO Stock options 2016 The Board [...]

High Seizure Frequency in Children with Dravet Syndrome Negatively Impacts Quality of Life, New International Caregiver Survey Finds

19/10/2017 - 08:00

Global survey of 584 caregivers of children, young adults and adults with Dravet illustrates the detrimental effect of debilitating, frequent seizures on quality of life and co-morbidities Results suggest a need for [...]

Nestlé reports nine-month sales for 2017

19/10/2017 - 07:16

This press release is also available in Français (pdf) and Deutsch (pdf) Follow today's event live 14:00 CEST Investor call audio webcast Full details in Events ............. Vevey, October 19, 2017 Nestlé reports nine- [...]

Semaglutide receives positive 16-0 vote in favour of approval from FDA Advisory Committee

18/10/2017 - 23:22

Bagsværd, Denmark, 18 October 2017 - Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0 in favour of the approval [...]

XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer

18/10/2017 - 16:52

AUSTIN, Texas, Oct. 18, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today enrollment of the first patient into a Phase I single arm study evaluating the maximum tolerated dose of Onivyde® (Irinotecan [...]

Arix Bioscience notes Harpoon Therapeutics' immuno-oncology collaboration with AbbVie

18/10/2017 - 14:33

Arix Bioscience notes Harpoon Therapeutics' immuno-oncology collaboration with AbbVie LONDON, 18 October 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience"), a global healthcare and life science company supporting [...]

InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC

18/10/2017 - 14:00

New 3D InSight(TM) Human Liver Fibrosis Model represents a powerful tool for screening efficacy and safety of anti-fibrotic drugs in vitro. Schlieren, Switzerland, Oct. 18, 2017 (GLOBE NEWSWIRE) -- InSphero AG, the [...]

Crown Bioscience partagera son expertise scientifique dans l'évaluation préclinique des molécules expérimentales anticancer lors de la Conférence internationale sur les cibles moléculaires et...

18/10/2017 - 13:49

Crown Bioscience partagera son expertise scientifique dans l'évaluation préclinique des molécules expérimentales anticancer lors de la Conférence internationale sur les cibles moléculaires et les agents thérapeutiques [...]